How would you treat a patient with metastatic urothelial carcinoma with early progression on maintenance immunotherapy?

It would depend on the clinical scenario, specifically the disease volume, degree of progression, and whether the patient is deriving clinical benefit despite radiographic progression. Significant early progression in a patient with high disease volume/symptoms is a poor prognostic indicator and we ...

Would continue and monitor by the measurable disease.